Phaseline

Targets › CDH17

CDH17 (Cadherin-17): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, Q12864)

Open in Phaseline: the race on CDH17, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chimeric TherapeuticsCHM-2101
Cadherin 17 (CDH17) chimeric antigen receptor (CAR) T cell therapy
CDH17Phase 1Neuroendocrine TumorsDec 2026
SOTIO BiotechSOT109
CDH17-directed antibody-drug conjugate with exatecan payload
CDH17Phase 1Colorectal Cancer (Locally Advanced or Metastatic)Nov 2027

Conditions

Colorectal Cancer (Locally Advanced or Metastatic) (1) Neuroendocrine Tumors (1)

Modalities

protein or peptide (1), other (1)

Companies

SOTIO Biotech (1) Chimeric Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.